Cadrenal Therapeutics, Inc. Common Stock (CVKD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cadrenal Therapeutics, Inc. Common Stock (CVKD) has a cash flow conversion efficiency ratio of -1.671x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.00 Million) by net assets ($1.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Cadrenal Therapeutics, Inc. Common Stock worth for the company's overall valuation and market capitalisation.
Cadrenal Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Cadrenal Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cadrenal Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cadrenal Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. See Cadrenal Therapeutics, Inc. Common Stock debt service capacity to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lisata Therapeutics Inc.
NASDAQ:LSTA
|
-0.332x |
|
Flour Mills Kepenos S.A.
AT:KEPEN
|
0.322x |
|
Glen Burnie Bancorp
NASDAQ:GLBZ
|
0.020x |
|
Xintela AB
ST:XINT
|
0.242x |
|
Eastern Technical Engineering Public Company Limited
BK:ETE
|
0.021x |
|
GENOMTEC S.A. ZY -10
F:4VI
|
N/A |
|
Vogiatzoglou Systems S.A
AT:VOSYS
|
0.047x |
|
DistIT AB (publ)
ST:DIST
|
-0.109x |
Annual Cash Flow Conversion Efficiency for Cadrenal Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Cadrenal Therapeutics, Inc. Common Stock from 2022 to 2025. View CVKD stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.74 Million | $-12.60 Million | -4.601x | -365.26% |
| 2024-12-31 | $7.44 Million | $-7.36 Million | -0.989x | -115.49% |
| 2023-12-31 | $7.69 Million | $-3.53 Million | -0.459x | -311.46% |
| 2022-12-31 | $-5.55 Million | $-1.20 Million | 0.217x | -- |
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with… Read more